Two new routes to make blood: Hematopoietic specification from pluripotent cell lines versus reprogramming of somatic cells

Sofie Singbrant, Peter van Galen, Daniel Lucas, Grant Challen, Derrick J. Rossi, George Q. Daley

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

Transplantation of hematopoietic stem cells (HSCs) to treat hematologic disorders is routinely used in the clinic. However, HSC therapy is hindered by the requirements of finding human leukocyte antigen (HLA)-matched donors and attaining sufficient numbers of long-term HSCs in the graft. Therefore, ex vivo expansion of transplantable HSCs remains one of the "holy grails" of hematology. Without the ability to maintain and expand human HSCs in vitro, two complementary approaches involving cellular reprogramming to generate transplantable HSCs have emerged. Reprogrammed HSCs represent a potentially inexhaustible supply of autologous tissue. On March 18th, 2015, Dr. George Q. Daley and Dr. Derrick J. Rossi, two pioneers in the field, presented and discussed their most recent research on these topics in a webinar organized by the International Society for Experimental Hematology (ISEH). Here, we summarize these seminars and discuss the possibilities and challenges in the field of hematopoietic specification.

Original languageEnglish
Pages (from-to)756-759
Number of pages4
JournalExperimental Hematology
Volume43
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint Dive into the research topics of 'Two new routes to make blood: Hematopoietic specification from pluripotent cell lines versus reprogramming of somatic cells'. Together they form a unique fingerprint.

Cite this